Durable Progression-Free and Treatment-Free Survival After Nivolumab Plus Ipilimumab Therapy in Metastatic Renal Cell Carcinoma: A Real-World Study with a 5-Year Minimum Follow-Up.

Ikoma H, Hamamoto S, Tasaki Y, Tomita M, Kawase K, Suzuki H, Noda Y, Usami M, Tsubouchi Y, Kato R, Sakata T, Mimura Y, Morikawa T, Nagai T, Unno R, Etani T, Naiki T, Sugiyama Y, Yasui T.

Open source

DOI: 10.3390/cancers18081315
Published: 2026-04-21
Container: Cancers (Basel)
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3390/cancers18081315,
  title = {Durable Progression-Free and Treatment-Free Survival After Nivolumab Plus Ipilimumab Therapy in Metastatic Renal Cell Carcinoma: A Real-World Study with a 5-Year Minimum Follow-Up.},
  author = {Ikoma H and  Hamamoto S and  Tasaki Y and  Tomita M and  Kawase K and  Suzuki H and  Noda Y and  Usami M and  Tsubouchi Y and  Kato R and  Sakata T and  Mimura Y and  Morikawa T and  Nagai T and  Unno R and  Etani T and  Naiki T and  Sugiyama Y and  Yasui T.},
  year = {2026},
  journal = {Cancers (Basel)},
  doi = {10.3390/cancers18081315},
  url = {https://doi.org/10.3390/cancers18081315}
}

RIS

TY  - JOUR
TI  - Durable Progression-Free and Treatment-Free Survival After Nivolumab Plus Ipilimumab Therapy in Metastatic Renal Cell Carcinoma: A Real-World Study with a 5-Year Minimum Follow-Up.
AU  - Ikoma H
AU  -  Hamamoto S
AU  -  Tasaki Y
AU  -  Tomita M
AU  -  Kawase K
AU  -  Suzuki H
AU  -  Noda Y
AU  -  Usami M
AU  -  Tsubouchi Y
AU  -  Kato R
AU  -  Sakata T
AU  -  Mimura Y
AU  -  Morikawa T
AU  -  Nagai T
AU  -  Unno R
AU  -  Etani T
AU  -  Naiki T
AU  -  Sugiyama Y
AU  -  Yasui T.
PY  - 2026
JO  - Cancers (Basel)
DO  - 10.3390/cancers18081315
UR  - https://doi.org/10.3390/cancers18081315
ER  -

APA

H, I., S, H., Y, T., M, T., K, K., H, S., Y, N., M, U., Y, T., R, K., T, S., Y, M., T, M., T, N., R, U., T, E., T, N., Y, S., & T., Y. (2026). Durable Progression-Free and Treatment-Free Survival After Nivolumab Plus Ipilimumab Therapy in Metastatic Renal Cell Carcinoma: A Real-World Study with a 5-Year Minimum Follow-Up.. Cancers (Basel). https://doi.org/10.3390/cancers18081315

Source records

europe-pmc · retrieved 2026-09-27T02:16:16.601Z